Company Overview
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -1529.3%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -1,529.33% |
Stock Price Performance
| 1 Year: | -28.40% |
| 6 Months: | -47.29% |
| 3 Months: | +29.04% |
| 1 Month: | -14.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 49.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PMN ProMIS Neurosciences, Inc. PHARMA | 12.53 | -0.99 | $112.37M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 7.46M | 10.18M | 11.75M | 10.77M | 8.64M |
| Operating Income | -1.11M | -2.07M | -3.94M | -4.86M | -6.05M | -4.97M | -2.90M | -2.52M | -3.68M | -2.71M | -4.43M | - | -7.46M | -10.18M | -11.75M | -10.77M | -8.64M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -7.46M | -10.12M | -11.58M | -10.67M | -8.64M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -7.35M | -10.12M | -11.58M | -10.67M | -8.24M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -225.54K | -1.21M | -2.09M | -2.75M | -5.96M | -4.96M | -2.31M | -2.36M | -3.64M | -2.62M | 9.28M | - | -7.35M | -10.12M | -11.58M | -10.67M | -8.24M |
| Diluted EPS | -0.06 | -0.20 | -0.29 | -0.38 | -0.83 | -0.58 | -0.27 | -0.19 | -0.19 | -0.13 | 0.31 | - | -5.27 | -7.25 | -6.00 | - | -5.27 |
| R&D Expense | 754.30K | 805.39K | 1.90M | 3.23M | 4.57M | 3.51M | 1.01M | 1.14M | 2.12M | 1.63M | 2.56M | - | 5.46M | 8.75M | 9.80M | - | 6.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 23.38M | 14.26M | 16.83M | 40.17M |
| Operating Income | - | -23.38M | -14.26M | -16.83M | -40.17M |
| EBITDA | - | -17.77M | -12.99M | 2.86M | -39.72M |
| Interest Expense | - | 282.06K | 201.39K | 76.78K | 0 |
| Pretax Income | - | -18.06M | -13.21M | 2.78M | -39.72M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -18.06M | -13.21M | 2.78M | -39.72M |
| Diluted EPS | - | -60.25 | -26.75 | 2.63 | -22.61 |
| R&D Expense | 4.63M | 16.09M | 7.88M | 10.64M | 33.38M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 6.92M | 13.62M | 18.91M | 9.18M |
| Current Assets | - | - | 6.90M | 13.62M | 18.91M | 9.18M |
| Cash & Equivalents | - | - | 5.88M | 12.60M | 13.29M | 6.12M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 71.63K | 78.64K | 78.03K | 36.52K |
| Total Liabilities | - | - | 8.27M | 9.87M | 2.42M | 10.44M |
| Current Liabilities | - | - | 6.41M | 9.35M | 2.22M | 10.41M |
| Long Term Debt | - | 3.91M | - | - | - | - |
| Total Debt | - | 3.91M | - | - | - | - |
| Total Equity | -796.66K | - | -1.35M | 3.75M | 16.49M | -1.26M |
| Shares Outstanding | - | - | 343.17K | 755.41K | 1.31M | 2.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -17.03M | -10.84M | -27.18M | -28.12M |
| Investing Cash Flow | - | -1.98K | -1.35K | -693 | -702 |
| Financing Cash Flow | - | 6.49M | 17.75M | 27.88M | 20.94M |
| Capital Expenditure | -6.04K | -1.98K | - | - | - |
| Free Cash Flow | - | -17.04M | -10.84M | -27.18M | -28.12M |
| Net Change in Cash | - | -10.54M | 6.90M | 693.02K | -7.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 1,340.2% | -352.0% | 16.9% | 3,155.8% |
| ROCE % | - | -4,569.9% | -334.1% | -100.8% | 3,267.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 14.42% | 1.29M | $18.11M |
| 2 | Deep Track Capital, Lp | 9.32% | 835.65K | $11.71M |
| 3 | Wellington Management Group, LLP | 7.77% | 696.38K | $9.76M |
| 4 | Ally Bridge Group (NY) LLC | 6.92% | 620.32K | $8.69M |
| 5 | Trails Edge Capital Partners, LP | 6.21% | 557.10K | $7.81M |
| 6 | Woodline Partners LP | 4.93% | 441.91K | $6.19M |
| 7 | Yu Fan | 3.68% | 329.76K | $4.62M |
| 8 | Sphera Funds Management Ltd. | 3.63% | 325.59K | $4.56M |
| 9 | Squadron Capital Management LLC | 3.62% | 324.98K | $4.55M |
| 10 | Ikarian Capital, LLC | 2.29% | 205.00K | $2.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PMN
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPbU42Z0xNV2pXQ0pXZEtJNWp6Mk85Nm0yQ2g4d3pCREdITkNLY0RTVVF6LUFUN1FydGcwb2xGai1FYXBycUZuZ3BaM0dBZXV1bEVtQVZoOU1iekVBRXRuZVNxRTBfMkxxNjEwWWtlb1NvTzcxbEk2ZGxLOXVTa0JndlJldm5oMTZVZmhNQz…
$PMN stock is up 16% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQRjI3S1ZwOHZ1X1FLeE5DT0xBVWZYd2kzR3dlR1UyTmJxOXpmdUc5V280STdrakszRUl1SU1fNEc1UWRYRUMyUUNndUkyajhlTXVjNjZCMzdVeFlnTnZwdEZXSWpUTU5ULTdsUzVPdWpFcGRsc1hrMlk3TVBFa24yZDNicktyRm9WX0syRW…
PMN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5iVGM1eGVDWGFQU0QyTU9OYU9idG5yRm9lMlFFTGd4SkdSRW9QVkJFcllCNnMtczY2LUZyR1QtUDlaYUxYNlEtdkdodWF5ckJBaFhpeVRYSkp4WXk5RDZnc1VHZTU3elU1eHZ1b0hubDBjZ0FncDFORA?oc=5" target="_blank">PMN F…
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE9NQmJnUzRaZ1gtQ18tc2VUOW5RUFBZTXJGeTB4bmVwZmJwdlBZdWJNREVOUmFQT1F2ZGk2ZnZrRGNaSmx2cUlwZ1gyWDN1QVFGR3pDSQ?oc=5" target="_blank">ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, …
PMN - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE1HNHRDUU1QZ0lfTk82VUhpQlR2YldJRi1LWVYtVTY5bEt6ZWY2M2ZNbWQ0amlUdXRraVlxeE4yLUJ6Vzc4?oc=5" target="_blank">PMN</a> <font color="#6f6f6f">Finviz</font>…
ProMIS Neurosciences stock jumps on trial safety data - Investing.com
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNWUJpZEc4cDNydkwzSjI1R3djWlotN1FjRFVXWlRwVmx0b2dQZF92RHR4cTdOTGRXQnBncFQ5YXFocjF1cHpwdERVajhnd3JQQzI1ZnFkLWZRdnd5TzdNX3NUb0JKTVIwVi1PU3I0YXh4aGZ6ZU9PM1lCYUozejdyOTExaC1vcHVxWXhiUk…
PMN — Frequently Asked Questions
What is the current share price of ProMIS Neurosciences, Inc. (PMN)?
As of 2026-09-19 21:16 PDT, ProMIS Neurosciences, Inc. (PMN) trades at $12.53 on NasdaqCM. Its 52-week range is $6.76 to $24.79.
What is the market capitalisation of PMN?
ProMIS Neurosciences, Inc. (PMN) has a market capitalisation of $112.37M on NasdaqCM.
What is the P/E ratio of PMN?
PMN trades at a trailing price-to-earnings (P/E) ratio of -0.99. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.54.
Is PMN a good stock to buy?
This page provides a data-driven analysis of ProMIS Neurosciences, Inc. (PMN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.